vs
Side-by-side financial comparison of AMERICAN PUBLIC EDUCATION INC (APEI) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $158.3M, roughly 1.1× AMERICAN PUBLIC EDUCATION INC). AMERICAN PUBLIC EDUCATION INC runs the higher net margin — 8.0% vs 1.6%, a 6.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -3.5%). Over the past eight quarters, AMERICAN PUBLIC EDUCATION INC's revenue compounded faster (1.3% CAGR vs -0.2%).
Strategic Education, Inc. (SEI) is an education services holding company and is formerly known as Strayer Education, Inc. The company owns for-profit, online Capella University and Strayer University, as well as non-degree programs schools such as DevMountain, Hackbright Academy, and Sophia Learning.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
APEI vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $158.3M | $177.4M |
| Net Profit | $12.6M | $2.9M |
| Gross Margin | 56.4% | — |
| Operating Margin | 12.0% | 3.9% |
| Net Margin | 8.0% | 1.6% |
| Revenue YoY | -3.5% | 5.0% |
| Net Profit YoY | -2.7% | — |
| EPS (diluted) | $0.67 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $158.3M | $196.9M | ||
| Q3 25 | $163.2M | $179.5M | ||
| Q2 25 | $162.8M | $181.1M | ||
| Q1 25 | $164.6M | $168.9M | ||
| Q4 24 | $164.1M | $187.3M | ||
| Q3 24 | $153.1M | $168.6M | ||
| Q2 24 | $152.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $12.6M | — | ||
| Q3 25 | $5.6M | $5.4M | ||
| Q2 25 | $4.5M | $-4.8M | ||
| Q1 25 | $8.9M | $4.8M | ||
| Q4 24 | $13.0M | — | ||
| Q3 24 | $2.3M | $-143.5M | ||
| Q2 24 | $371.0K | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 56.4% | 79.5% | ||
| Q3 25 | 54.2% | 80.9% | ||
| Q2 25 | 51.8% | 77.4% | ||
| Q1 25 | 54.5% | 79.7% | ||
| Q4 24 | 56.3% | 78.7% | ||
| Q3 24 | 50.8% | 76.9% | ||
| Q2 24 | 50.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 12.0% | 1.2% | ||
| Q3 25 | 5.9% | 3.5% | ||
| Q2 25 | 4.3% | 4.7% | ||
| Q1 25 | 7.4% | 1.2% | ||
| Q4 24 | 13.1% | 13.2% | ||
| Q3 24 | 2.7% | -82.8% | ||
| Q2 24 | 1.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 8.0% | — | ||
| Q3 25 | 3.4% | 3.0% | ||
| Q2 25 | 2.8% | -2.7% | ||
| Q1 25 | 5.4% | 2.8% | ||
| Q4 24 | 7.9% | — | ||
| Q3 24 | 1.5% | -85.1% | ||
| Q2 24 | 0.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.67 | $0.05 | ||
| Q3 25 | $0.30 | $0.12 | ||
| Q2 25 | $-0.02 | $-0.11 | ||
| Q1 25 | $0.41 | $0.10 | ||
| Q4 24 | $0.63 | $0.38 | ||
| Q3 24 | $0.04 | $-3.11 | ||
| Q2 24 | $-0.06 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $174.1M | $144.3M |
| Total DebtLower is stronger | $94.7M | — |
| Stockholders' EquityBook value | $294.8M | $653.9M |
| Total Assets | $521.4M | $1.2B |
| Debt / EquityLower = less leverage | 0.32× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $174.1M | $238.4M | ||
| Q3 25 | $191.3M | $246.3M | ||
| Q2 25 | $174.9M | $445.9M | ||
| Q1 25 | $161.6M | $493.6M | ||
| Q4 24 | $131.9M | $484.6M | ||
| Q3 24 | $135.4M | $453.8M | ||
| Q2 24 | $129.8M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $94.7M | $372.2M | ||
| Q3 25 | $94.4M | $376.7M | ||
| Q2 25 | $94.1M | $580.5M | ||
| Q1 25 | $93.7M | $583.4M | ||
| Q4 24 | $93.4M | $585.3M | ||
| Q3 24 | $93.1M | — | ||
| Q2 24 | $92.8M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $294.8M | $693.1M | ||
| Q3 25 | $279.3M | $727.2M | ||
| Q2 25 | $272.2M | $757.8M | ||
| Q1 25 | $310.0M | $798.5M | ||
| Q4 24 | $303.9M | $778.3M | ||
| Q3 24 | $290.4M | $749.6M | ||
| Q2 24 | $288.7M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $521.4M | $1.3B | ||
| Q3 25 | $525.3M | $1.3B | ||
| Q2 25 | $537.4M | $1.5B | ||
| Q1 25 | $578.7M | $1.6B | ||
| Q4 24 | $570.1M | $1.6B | ||
| Q3 24 | $569.6M | $1.5B | ||
| Q2 24 | $560.7M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.32× | 0.54× | ||
| Q3 25 | 0.34× | 0.52× | ||
| Q2 25 | 0.35× | 0.77× | ||
| Q1 25 | 0.30× | 0.73× | ||
| Q4 24 | 0.31× | 0.75× | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.32× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.6M | — |
| Free Cash FlowOCF − Capex | $-15.6M | — |
| FCF MarginFCF / Revenue | -9.9% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | -0.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | $46.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-11.6M | $43.7M | ||
| Q3 25 | $21.7M | $60.8M | ||
| Q2 25 | $14.8M | $12.0M | ||
| Q1 25 | $37.0M | $35.5M | ||
| Q4 24 | $1.6M | $33.1M | ||
| Q3 24 | $14.1M | $53.9M | ||
| Q2 24 | $12.5M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-15.6M | $43.5M | ||
| Q3 25 | $17.5M | $57.0M | ||
| Q2 25 | $11.1M | $9.3M | ||
| Q1 25 | $33.1M | $26.9M | ||
| Q4 24 | $-1.8M | $31.0M | ||
| Q3 24 | $7.8M | $49.8M | ||
| Q2 24 | $7.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -9.9% | 22.1% | ||
| Q3 25 | 10.7% | 31.7% | ||
| Q2 25 | 6.8% | 5.1% | ||
| Q1 25 | 20.1% | 15.9% | ||
| Q4 24 | -1.1% | 16.6% | ||
| Q3 24 | 5.1% | 29.6% | ||
| Q2 24 | 4.7% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.6% | 0.1% | ||
| Q3 25 | 2.6% | 2.2% | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 5.1% | ||
| Q4 24 | 2.0% | 1.1% | ||
| Q3 24 | 4.1% | 2.4% | ||
| Q2 24 | 3.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.92× | — | ||
| Q3 25 | 3.90× | 11.20× | ||
| Q2 25 | 3.29× | — | ||
| Q1 25 | 4.16× | 7.37× | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 6.22× | — | ||
| Q2 24 | 33.57× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APEI
| American Public Education Inc Segment | $71.0M | 45% |
| Rasmussen University Segment | $66.6M | 42% |
| Hondros College Of Nursing Segment | $20.7M | 13% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
